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Abstract
Background: General practice-based (GP) healthcare data have promise, when systematically collected, to support
estimating local rates of chronic obstructive pulmonary disease (COPD) and asthma, variations in burden of disease, risk
factors and comorbid conditions, and disease management and quality of care. The use of GP information systems for
health improvement has been limited, however, in the scope and quality of data. This study assessed the practical utility of
de-identified clinical databases for estimating local rates of COPD and asthma. We compared COPD and asthma rates to
national benchmarks, examined health related risk factors and co-morbidities as correlates of COPD and asthma, and
assessed spatial patterns in prevalence estimates at the small-area level.
Methods: Data were extracted from five GP databases in western Adelaide, South Australia, for active patients residing in
the region between 2012 and 2014. Prevalence estimates were computed at the statistical area 1 (SA1) spatial unit level
using the empirical Bayes estimation approach. Descriptive analyses included summary statistics, spatial indices and mapping
of geographic patterns. Bivariate associations were assessed, and disease profiles investigated to ascertain multi-morbidities.
Multilevel logistic regression models were fitted, accounting for individual covariates including the number of comorbid
conditions to assess the influence of area-level socio-economic status (SES).
Results: For 33,725 active patients, prevalence estimates were 3.4% for COPD and 10.3% for asthma, 0.8% higher and 0.5%
lower for COPD and asthma, respectively, against 2014–15 National Health Survey (NHS) benchmarks. Age-specific
comparisons showed discrepancies for COPD in the ‘64 years or less’ and ‘age 65 and up’ age groups, and for asthma in the
‘15–25 years’ and ‘75 years and up’ age groups. Analyses confirmed associations with individual-level factors, co-morbid
conditions, and area-level SES. Geographic aggregation was seen for COPD and asthma, with clustering around GP clinics
and health care centres. Spatial patterns were inversely related to area-level SES.
Conclusion: GP-based data capture and analysis has a clear potential to support research for improved patient outcomes
for COPD and asthma via knowledge of geographic variability and its correlates, and how local prevalence estimates differ
from NHS benchmarks for vulnerable age-groups.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is a pro-
gressive condition that affects the respiratory and circula-
tory systems, and is most often caused by the inhalation of
noxious particulates or gases which in turn stimulate an ab-
normal inflammatory response from the airways and the
lungs [1–4]. Asthma, on the other hand, is a common
chronic disorder of the airways which is complex with
variable and recurring symptoms of airflow obstruction,
bronchial hyper-responsiveness, and an underlying inflam-
mation [5]. It is characterised by reversible (or partly revers-
ible) intermittent or chronic airway inflammation and
respiratory symptoms such as wheezing, shortness of
breath, chest tightness, and coughing which vary over time
and in intensity [1–4]. Both COPD and asthma can co-exist
in the same patient posing diagnostic and therapeutic chal-
lenges. This correspondence has been recognized by a joint
committee of the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) and the Global Initiative for Asthma
(GINA) as the “asthma-COPD overlap” (ACO) syndrome.
While there remains controversy as to whether this overlap
constitutes a syndrome [2–4, 6], important features distin-
guish typical COPD from typical asthma. For example,
people with COPD continue to lose lung function despite
taking medication, not a common feature of asthma [7].
People with COPD and/or asthma rate their health worse
than people without these conditions [7, 8]. In the later
stages of COPD, the inflammatory response interferes with
normal breathing patterns and exercise tolerance, resulting
in poor quality of life and dependence on community and
carer support [8, 9]. Disease management is difficult and
hospitalisation for episodes of acute illness is common, with
longer duration of admissions compared to other chronic
conditions [10]. Despite declining mortality rates for
asthma and COPD in Australia [11], the asthma death rate
remains high compared with many other countries while
COPD is a leading cause of death both domestically and
internationally [12]. Both COPD and asthma are potentially
preventable hospitalisation conditions, with COPD the sec-
ond leading cause of avoidable hospital admissions [13].
Geographically varying socio-economic correlates and
risk factors exist for COPD and asthma, including genetic
disposition, behavioural and environmental factors [1, 14,
15]. Most of the people develop COPD through environ-
mental exposures to air pollutants and deleterious gases,
particularly, the exposure to tobacco smoke including sec-
ond hand smoke. Other significant and spatially varying en-
vironmental sources include emissions from local
industries, proximity to major roads and heavy traffic, occu-
pational exposures to dust, particularly among workers in
coal mining or livestock farming [1, 14]. Early diagnosis
and secondary prevention can be achieved through screen-
ing and close monitoring by general practitioners (GPs)
[16–18]. But GPs often do not have the capacity to screen
for patients at risk and, consequently, most of cases are de-
tected in the latter stages of the disease when symptoms be-
come pronounced and/or begin to impair patient’s quality
of life [19, 20]. This situation presents an opportunity for
improvement as, in Australia, 75% of all medical consulta-
tions take place in GP’s offices, and more than 85% of the
population access a GP each year [21]. Providing GPs with
the knowledge of what the rates of COPD and asthma are
in their local area, the levels of risk in the local community,
and the characteristics of patient catchment areas could en-
able GPs to provide improved patient care [22–25].
COPD and asthma are exemplar conditions by which to
illustrate how GP data capture and analysis can aid in un-
derstanding the local features of important diseases and
pertinent care. GP-based data can offer an important
source of real-world information on the populations acces-
sing practices, and local-area living conditions. Spatial ana-
lyses of GP-based data can assist to better understand
geographic distributions of patients’ health status and out-
comes, and inform local health services improvements.
Thus far, however, the use of GP-based clinical information
systems for data collection and health improvement has
been limited in both extent and quality. Models such as the
Practice Health Atlas (PHA) have been used to develop a
professional culture around quality health data [26] and
platforms such as the Bettering the Evaluation and Care of
Health (BEACH) and the Melbourne East Monash General
Practice Database (MAGNET) have been developed to pro-
vide unique and high-quality GP research databases [27,
28]. These models should be extended to the entire Austra-
lian GP body to unlock the potential of high-quality GP
data for high-quality research contributing to improved
local and global patients’ health outcomes [24, 26–28].
In 2012–13, a Medicare Local-based intervention pro-
gram to improve GP data quality and reduce GP-based
COPD under-diagnosis was implemented in the western
region of Adelaide, South Australia (Fig. 1). Baseline data
from five large practices in the area indicated that, com-
pared to the national benchmark, there was a much
lower overall rate of COPD (2% of GP population un-
diagnosed) [29]. Within 6 months of the program, the
proportion of patients with a diagnosis of COPD in-
creased on average by 20% [29]. The purpose of the
current study was to use GP-based de-identified clinical
data from five practices who participated in the above
intervention program with aims to address: 1) the prac-
tical use of GP-based data for estimating localized
COPD and asthma spatial prevalence rates, comparing
GP-based rates with national rates; 2) the use of
GP-based data to examine risk factors and comorbid
conditions associated with COPD and asthma; and 3)
whether spatial clustering exists in COPD and asthma
prevalence rates, and if so, whether such clustering var-
ies according to area-level socio-economic status (SES).
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Methods
Source of data
Data were extracted from five “sentinel” GP practices
participating in the Medicare Local GP-based data im-
provement program in the western area of Adelaide,
South Australia, including the LeFevre Peninsula and its
closest surrounding areas. Figure 1 displays the study re-
gion according to the Australian Bureau of Statistics
(ABS) census unit, statistical area 1 (SA1) [30]. “Senti-
nel” GP practices were chosen for the availability of
higher-quality GP data and the need to understand
population factors related to chronic disease. Analyses
were restricted to “active” patients living within the
study area and seen by their GP between 2012 and 2014.
An “active” patient was defined per the Royal Australian
College of General Practitioners (RACGP) criterion as
one who attended the practice three times or more
within the past two years [31].
GP clinical data from this region have previously been
used to examine spatial variation of cardiovascular disease
at small geographic area levels and to estimate community
level prevalence of undiagnosed diabetes [32, 33]. There
were 486 SA1s in the study area. Table 1 below presents
the five practices included in the analysis and their respect-
ive records of total and active patients within the study
area. There were 33,725 active patients who visited GP
practices with 3 progress notes recorded. The de-identified
GP clinical records included the risk factors age, sex, smok-
ing status, Aboriginal or Torres Strait Islander status
(ATSI), and marital status. Respiratory health conditions
under study (outcome variables) were COPD, asthma, and
ACO. Recorded comorbidities included type 2 diabetes,
heart failure, stroke, peripheral vascular disease, mental dis-
order, dementia and osteoarthritis/osteoporosis. Variables
relating to respiratory health conditions, risk factors and
comorbidities were coded in accordance with value domain
attributes listed on the Australian Institute of Health and
Welfare (AIHW) Metadata Online Registry (Meteor). Re-
spiratory health conditions were classified as “active” if ac-
tive at the time of the extract; “inactive” and “never
diagnosed” conditions were combined and classified as the
absence of a condition. The classification of active COPD
was satisfied by a record of either active respiratory COPD
or active chronic obstructive airways disease. Finally, the
2011 census index of relative socio-economic disadvantage
(IRSD), one of the socio-economic index of areas (SEIFA)
variants, was obtained from the Australian Bureau of Statis-
tics (ABS) [34].
The 2014–15 National Health Survey (NHS), the most
recent in a series of Australia-wide health surveys con-
ducted by the ABS, provided information on national
prevalence estimates of chronic respiratory conditions by
pre-defined age groups [7]. The NHS was designed to col-
lect a range of information about the health of Australians,
Fig. 1 Delimitation of the study area and SA1 counts of active patients
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including: prevalence of long-term health conditions; health
risk factors such as smoking, overweight and obesity, alco-
hol consumption and exercise; use of health services such
as consultations with health practitioners and actions
people have recently taken for their health; and demo-
graphic and socio-economic characteristics.
Both prevalence rates and standardised prevalence ratios
(SPR) of COPD and asthma were calculated by SA1 geo-
graphic areas. Prevalence estimates were adjusted for the
number of active patients in each SA1 using the empirical
Bayes estimation approach [35]. SPRs were computed as the
ratio of observed to expected number of cases in each area,
where the expected number of cases was determined ac-
cording to the age distribution of patients within each SA1.
Specifically, expected levels of risk were attributed to pa-
tients based on their age groups: 0–14, 15–24, 25–34, 35–
44, 45–54, 55–64, 65–74, 75–84 and 85+, and associated na-
tionwide estimates of asthma and COPD risks for these age
groups from 2014 to 15 NHS data [7]. Expected risk was
then summed across all patients in the SA1 to determine
the expected number of cases. These SPRs were purposively
calculated to highlight under- or over-diagnosed areas.
Area-level prevalence and SPRs estimates were mapped to
highlight the geographic variation of COPD and asthma.
Descriptive and inferential analyses
Descriptive analyses consisted of summary statistics,
spatial indices (for spatial clustering) and mapping of geo-
graphical patterns. Summary statistics included descriptive
statistics pertaining to: (1) the prevalence of diagnosed re-
spiratory health conditions (COPD, asthma, and ACO)
among active patients in the study area; and (2) the preva-
lence of these diagnosed respiratory conditions across dis-
tinct age groups, benchmarked against NHS data for the
years 2014–15 [7]. Bivariate associations between these di-
agnosed respiratory conditions and individual risk factors
and comorbidities were assessed, and between-group dif-
ferences tested for statistical significance using Pearson’s
chi-square test or Fisher’s exact test where observed cell
numbers were small. Chronic disease profiles were investi-
gated for multi-morbidities and a multi-morbidity matrix
that reflected the number and percentage of patients with
co-occurring conditions was calculated.
To assess whether area-level SES, measured by
SEIFA-IRSD, was related to COPD and asthma preva-
lence rates, multilevel logistic regression models of ac-
tive COPD and asthma among patients nested within
SA1s were performed (for inferential analysis [36]), ac-
counting for basic individual socio-demographic covari-
ates (age, sex, smoking status, marital status and ATSI)
and the number of comorbid conditions. All covariates
were categorical, except age which was modelled as a
standardized continuous variable. Linear and quadratic
age terms were incorporated in the models.
Distributions of COPD and asthma cases were mapped
and the degree to which cases were clustered spatially
(spatial autocorrelation, ‘Hot’ and ‘cold’ spots) was assessed
using indices of spatial associations. Global Moran’s I (for
spatial autocorrelation) and local Getis-Ord’s Gi* (for hot
or cold spots) indices were computed [37, 38]. Bivariate
choropleth maps of COPD and asthma prevalence against
SEIFA-IRSD were created to visualise the extent of geo-
graphic overlap in spatial clustering patterns of each
measure at the SA1 level. SEIFA-IRSD and estimated
prevalence values were, for each variable, split into
quartiles, and then the variables were overlayed to indicate




Overall observed prevalence estimates were 3.4, 10.3
and 0.9% for COPD, asthma and ACO respectively
(Table 2). As expected, COPD was more prevalent in
the 55 years and over group (7.8%) while asthma was
more prevalent in the up to 34 years group (11.7%). At
the practice level, overall prevalence estimates for
COPD and asthma were less than national self-reported
prevalence benchmarks (2.6 and 10.8% for COPD and
asthma respectively) at one (COPD) and three (asthma)
of the five practices analysed (Tables 3 and 4). Con-
versely, more COPD cases than expected were observed
Table 1 Counts of total patients and active patients recorded by each practice in the initial database and restricted to residents of
the study area
Initial database records Restricted study area
Practice ID Total patients Active patients Total patients Active patients
Practice 1 25,062 13,655 18,958 12,032
Practice 2 23,161 9858 17,551 8004
Practice 3 24,838 9349 15,548 7085
Practice 4 8301 4690 6863 4140
Practice 5 8098 2919 6198 2464
Total 89,460 40,471 65,118 33,725
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at one of the five practices analysed, and more asthma
cases than expected at two of the five (Tables 3 and 4).
Overall SPR values were 0.92 and 0.96 for COPD and
asthma respectively, indicating both COPD and asthma
under-diagnosis from GP data.
Although data from these “sentinel” GP practices indi-
cated a 0.8% higher overall rate of COPD and a 0.5% lower
overall rate of asthma (compared to national benchmarks),
prevalence estimates were lower than the benchmark be-
fore age 65 (0.6% lower for those aged 15–24, and 1.0%
lower for those aged 35–44) but higher than the bench-
mark for age 65 years and over (0.5, 2.2 and 2.1% higher for
the age groups 65–74, 75–84 and 85+) for COPD (Fig. 2a).
For asthma, prevalence estimates in those aged 15–24 and
85+ were 3.4 and 2.5% higher, respectively, than the bench-
mark. On the other hand, asthma under-diagnosis was ap-
parent between age 25 and 74 years, up to 3.7% lower for
those aged 55–64 years (Fig. 2b).
COPD, asthma, risk and/or comorbid conditions
Differences in prevalence estimates for active respira-
tory conditions for patients defined according to their
status on a given risk factor, or the presence/absence
of another health condition, highlight the magnitude
of association between COPD and asthma with risk
factors and comorbid conditions (Table 5). Analyses
of COPD generally yielded strong statistically signifi-
cant associations with known individual-level factors
and comorbid conditions (all p-values < 0.0001), ex-
cept for ATSI status. For asthma, prevalence rates
were statistically significantly different across levels of
individual-level characteristics, except smoking status.
Asthma prevalence rates also differed significantly in
relation to examined comorbid conditions, except for
peripheral vascular disease, stroke and dementia for
which associations were statistically non-significant.
Within the five GP practices, 50.7% of patients had at least
one chronic condition, and 21.1% at least two conditions.
For patients with COPD, 83.7% had at least two additional
chronic conditions including asthma. For patients with
asthma, 59.8% had at least two additional chronic conditions
including COPD. As shown in Table 6, prevalent
co-occurring chronic conditions among patients with COPD
included osteoarthritis/osteoporosis (48.7%), asthma (28.1%)
and mental health disorder (27.4%). For co-occurring
chronic conditions with asthma, besides COPD-asthma, the
most frequent condition was mental health disorder (23.3%)
followed by osteoarthritis/osteoporosis (22.4%).
Among patients aged 55 years and over (of whom 7.8%
were diagnosed with COPD, and 9.8% with asthma),
72.2% had at least one other chronic condition and,
84.5% of COPD patients and 86.3% of asthma patients
Table 2 Prevalence of active COPD, asthma, and combined asthma-COPD overlap among active patients in the study area
COPD Asthma Overlap (COPD + asthma) Total (row n)
All active patients n % n % n % n
1130 3.4 3457 10.3 317 0.9 33,725
By age group n % n % n % n
0–14 2 0.0 524 10.9 1 0.0 4789
15–24 0 0.0 474 14.2 0 0.0 3328
25–34 10 0.3 363 10.2 3 0.1 3561
35–44 19 0.5 391 9.4 6 0.1 4180
45–54 82 1.7 432 8.9 24 0.5 4846
55–64 190 4.2 389 8.7 50 1.1 4479
65–74 288 7.5 379 9.9 77 2.0 3846
75–84 359 11.1 364 11.3 103 3.2 3221
85+ 180 12.2 141 9.6 53 3.6 1474
Table 3 Prevalence and standardised prevalence ratios of COPD by medical practice
Active patients Observed cases Expected cases Prevalence (=O/A*100%) SPR (=O/E)
Practice 1 12,032 374 409 3.1 0.91
Practice 2 8004 345 290 4.3 1.19
Practice 3 7085 243 269 3.4 0.90
Practice 4 4140 103 154 2.5 0.67
Practice 5 2464 65 77 2.6 0.84
Total 33,725 1130 1228 3.4 0.92
Note: SPR Standardised prevalence ratio
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had at least two additional conditions. Prevalent pairs of
co-occurrence conditions were asthma-osteoarthritis/
osteoporosis (53.7%) and COPD-osteoarthritis/osteopor-
osis (51.9%), followed by asthma-mental health disorder
(29.3%) and COPD-asthma (29.3%) (Table 7).
COPD, asthma and SEIFA - index of relative social
disadvantage
Results of multilevel models to assess the effects of
area-level SES (SEIFA-IRSD) on COPD and asthma
prevalence rates, adjusting for patient characteristics, are
presented in Tables 8 and 9. The unadjusted model of
COPD and area-level SES relationships exhibited a sig-
nificant negative gradient from the least (Q4) to the
most (Q1) disadvantaged quartile groups. This gradient
was also observed in the adjusted model, where the esti-
mated risk of COPD among patients residing in the
most disadvantaged SA1s (Q1) was 1.67 times greater
than that of patients in least disadvantaged SA1s (OR =
1.670; 95% CI: 1.168–2.387). These patients (from SA1s
Table 4 Prevalence and standardised prevalence ratios of asthma by medical practice
Active patients Observed cases Expected cases Prevalence (=O/A*100%) SPR(=O/E)
Practice 1 12,032 1320 1297 11.0 1.02
Practice 2 8004 815 855 10.2 0.95
Practice 3 7085 828 753 11.7 1.10
Practice 4 4140 332 440 8.0 0.76
Practice 5 2464 162 266 6.6 0.61
Total 33,725 3457 3605 10.3 0.96
Note: SPR Standardised prevalence ratio
A
B
Fig. 2 a Prevalence of COPD by age group in study area versus NHS statistics with 95% confidence intervals. b Prevalence of Asthma by age
group in study area versus NHS statistics with 95% confidence intervals
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Table 5 Respiratory conditions within risk factors/comorbidities groups (count & prevalence)
COPD Asthma ACO (COPD + asthma) Total (row n)
n % n % n % n
All active patients 1130 3.4 3457 10.3 317 0.9 33,725
Risk factors
Age **** **** **** 33,724
Under 55 113 0.5 2184 10.5 34 0.2 20,704
55 to 69 327 4.9 595 9.0 83 1.2 6648
70 to 84 510 10.4 537 11.0 147 3.0 4898
85 and over 180 12.2 141 9.6 53 3.6 1474
Sex **** **** 33,627
Male 591 4.1 1380 9.6 138 1.0 14,375
Female 539 2.8 2073 10.8 179 0.9 19,252
Smokinga **** **** 25,688
Daily/irregular 298 7.8 442 11.6 63 1.7 3807
Ex-smoker 518 8.9 660 11.3 148 2.5 5839
Never smoked 236 1.5 1775 11.1 85 0.5 16,042
Indigenous Australian ** 15,304
Yes 15 5.4 45 16.1 4 1.4 280
No 565 3.8 1618 10.8 185 1.2 15,024
Marital status **** **** **** 9853
Never married 97 2.8 423 12.1 29 0.8 3496
Married/De facto 221 4.3 470 9.1 53 1.0 5167
Divorced/Separated 41 7.8 67 12.7 12 2.3 526
Widowed 66 9.9 92 13.9 23 3.5 664
Comorbid conditions
Diabetes (type II) **** ** **** 33,725
Yes 184 7.7 291 12.1 58 2.4 2399
No 946 3.0 3166 10.1 259 0.8 31,326
Heart failure **** **** **** 33,725
Yes 91 20.0 79 17.3 35 7.7 456
No 1039 3.1 3378 10.2 282 0.8 33,269
Stroke **** **** 33,725
Yes 66 12.0 68 12.3 16 2.9 552
No 1064 3.2 3389 10.2 301 0.9 33,173
Peripheral vascular disease **** ** 33,725
Yes 37 23.9 12 7.7 6 3.9 155
No 1093 3.3 3445 10.3 311 0.9 33,570
Mental disorder **** **** **** 33,725
Yes 310 5.8 804 15.0 99 1.8 5362
No 820 2.9 2653 9.4 218 0.8 28,363
Dementia **** * 33,725
Yes 26 10.1 22 8.6 7 2.7 257
No 1104 3.3 3435 10.3 310 0.9 33,468
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in Q1) faced also a risk of COPD 1.169 times greater
than patients from SA1s in Q2 (OR = 1.169; 95% CI:
0.977–1.398), although this association was at the bor-
derline of statistical significance (Table 8). The adjusted
model additionally confirmed the importance of
individual-level covariates on the prevalence of COPD,
especially the number of comorbid conditions as well as
age, sex and smoking status.
For asthma and area-level SES relationships, the un-
adjusted model resulted in a non-linear negative
trend, whereby the comparison of the least (Q4) to
the most (Q1) disadvantaged quartile groups was not
statistically significant as might be expected from pre-
vious studies (Table 9). As shown in the model
adjusting for individual-level covariates and numbers
of comorbid conditions, this negative trend was re-
versed when comparing the fourth and third quartile
groups (Q4, Q3) to the most disadvantaged (Q1)
group. Only the comparison of the least (Q4) to the
most (Q1) disadvantaged quartile groups was statisti-
cally significant, with the prevalence of asthma 1.44
times greater in the least disadvantaged SA1s (Q4)
compared to the most disadvantaged SA1s (OR =
1.435; 95% CI: 1.196–1.723) (Table 9). The adjusted
model confirmed the importance of individual-level
covariates other than ATSI and marital status,
particularly the number of comorbid conditions which
exerted a strong influence and was responsible for
the shift from the negative non-linear trend observed
in the non-adjusted model.
Spatial patterns of COPD, asthma and SEIFA - index of
relative social disadvantage
Both COPD and asthma cases were not randomly dis-
tributed throughout the study region, but exhibited
degrees of geographic aggregation. For COPD, low
prevalence values were observed for western coastal
areas, with some pockets of high prevalence. High
prevalence areas were observed for northern regions,
towards the east to the periphery of the central busi-
ness district, and in the south, close to the airport
(Fig. 3). For asthma diagnoses, areas with high preva-
lence values were observed in the northern region
and the northwest-southeast axis of the study region.
The southwest, south and southeast regions had low
prevalence values in general, but these were punctu-
ated with pockets of high prevalence (Fig. 3).
Both COPD and asthma prevalence values exhibited
global and local spatial relationships. The Moran’s I statis-
tic for COPD (I = 0.033, p = 0.002) indicated a positive and
statistically significant spatial autocorrelation (small-scale
variation) with the clustering of one large hot spot, two
Table 5 Respiratory conditions within risk factors/comorbidities groups (count & prevalence) (Continued)
COPD Asthma ACO (COPD + asthma) Total (row n)
n % n % n % n
Osteoarthritis/ osteoporosis **** **** **** 33,725
Yes 550 9.7 776 13.6 189 3.3 5698
No 580 2.1 2681 9.6 128 0.5 28,027
Note: Pearson Chi-square test: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; Mental disorder: any active anxiety, depression or bipolar disorder; Row totals do
not always add to the total number of active patients due to missing data; aMissing data on smoking within active COPD (n = 78, 6.9%); asthma (n = 580, 17%);
ACO (n = 21, 6.6%)
Stars (***) inside Table 5 indicate the levels of the Pearson Chi-square test p-values (p); *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001
Table 6 Percentage of patients with an active condition (rows) that also have an additional active condition (columns)
Condition B
Condition A Row n Row % COPD Asthma OA/Osteo Mental Diabetes Stroke Heart fail Dementia PVD
COPD 1130 3.35 100 28.1 48.7 27.4 16.3 5.84 8.05 2.30 3.27
Asthma 3457 10.3 100 22.4 23.3 8.42 1.97 2.29 0.64 0.35
OA/Osteo condition 5698 16.9 100 28.7 16.5 5.76 4.97 2.49 1.67
Mental disorder 5362 15.9 100 10.3 3.02 2.16 1.90 0.67
Diabetes type II 2399 7.11 100 5.42 4.50 2.25 2.00
Stroke 552 1.64 100 10.3 5.43 2.72
Heart failure 456 1.35 100 6.36 4.39
Dementia 257 0.76 100 2.72
PVD 155 0.46 100
Overall prevalence of Condition B 3.35 10.3 16.9 15.9 7.11 1.64 1.35 0.76 0.46
Note – OA/Osteo condition osteoarthritis or osteoporosis, Mental disorder any active anxiety, depression or bipolar disorder, PVD peripheral vascular disease
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very small-size hot spots and two relatively medium-size
cold spots (Fig. 4). For asthma prevalence, the Moran’s I
statistic (I = 0.0178, p = 0.076) indicated positive global
spatial relationship, but at the borderline of statistical sig-
nificance. The clustering of high values (one medium-size
hot spot) and low values (one relatively large cold spot)
are illustrated in Fig. 4.
Geographic patterns of the index of relative social disad-
vantage (SEIFA-IRSD) highlighted the coastal west and
southwest region with relatively well-off areas with social
disadvantage increasing towards the north, close to the
peninsula and towards both the east and southeast regions
(Fig. 5). Overlaying choropleth maps of COPD and asthma
prevalence rates with relative socio-economic disadvantage
Table 7 Percentage of patients aged 55 years and over with an active condition (rows) that also have an additional active condition
(columns)
Condition B
Condition A Row n Row % COPD Asthma OA/Osteo Mental Diabetes Stroke Heart fail Dementia PVD
COPD 1017 7.81 100 27.8 51.9 25.4 17.7 6.49 8.95 2.56 3.54
Asthma 1273 9.78 100 53.7 29.3 19.2 5.26 6.05 1.65 0.86
OA/Osteo condition 5105 39.2 100 27.4 17.7 6.39 5.45 2.76 1.84
Mental disorder 2618 20.1 100 17.6 5.77 4.35 3.86 1.38
Diabetes type II 2074 15.9 100 6.17 5.16 2.60 2.31
Stroke 527 4.05 100 10.8 5.50 2.85
Heart failure 442 3.40 100 6.56 4.52
Dementia 253 1.94 100 2.77
PVD 150 1.15 100
Overall prevalence of Condition B 7.81 9.78 39.2 20.1 15.9 4.05 3.40 1.94 1.15
Note – OA/Osteo condition osteoarthritis or osteoporosis, Mental disorder any active anxiety, depression or bipolar disorder, PVD peripheral vascular disease
Table 8 Multilevel logistic regression of active COPD
Model 1 Model 2
Covariates Est. SE p [95% CI] Est. SE p [95% CI]
Within-cluster
Age – – – – – 2.348 0.239 < 0.0001 [1.880 2.816]
Age2 – – – – – − 0.697 1.121 < 0.0001 [− 0.933 − 0.461]
Male – – – – – 0.522 0.077 < 0.0001 [0.372 0.672]
Female – – – – – 0.0 – – – –
Smoker – – – – – 2.477 0.116 < 0.0001 [2.251 2.704]
Ex-smoker – – – – – 1.522 0.093 < 0.0001 [1.340 1.704]
Never smoked – – – – – 0.0 – – – –
Indigenous Australian – – – – – 0.871 0.341 0.011 [0.203 1.540]
Non-Indigenous Australian – – – – – 0.0 – – – –
Unmarried – – – – – 0.365 0.126 0.004 [0.118 0.613]
Married – – – – – 0.0 – – – –
N-Comorbidities – – – – – 1.060 0.029 < 0.0001 [1.004 1.117]
Between-cluster – –
IRSD (Q4) −1.280 0.171 < 0.0001 [−1.614 −0.945] − 0.513 0.182 0.005 [−0.870 − 0.155]
IRSD (Q3) −0.712 0.114 < 0.0001 [−0.936 − 0.489] − 0.299 0.117 0.010 [− 0.528 − 0.071]
IRSD (Q2) − 0.358 0.083 < 0.0001 [− 0.520 − 0.196] − 0.156 0.091 0.088 [− 0.335 0.023]
IRSD (Q1) 0.0 – – – – 0.0 – – – –
Notes – Age: age in years, standardised; Age2: Age*Age. Smoker: daily, weekly or irregular smoker; Ex-smoker: does not smoke now, but has smoked ≥ 100
cigarettes (or equivalent) in life time; Never smoked: does not smoke now, and has smoked < 100 cigarettes (or equivalent) in life time; Unmarried: never married,
divorced, separated or widowed; Married: registered or de facto; N-Comorbidities: Number of comorbid conditions; IRSD: Index of Relative Social Disadvantage
(ABS 2011); Q1-Q4: National quartile of IRSD (determined using cut-points for quartiles within the Australia-wide distribution of scores at SA1 level) where Q1:
most disadvantaged, Q4: least disadvantaged
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Table 9 Multilevel logistic regression of active asthma
Model 1 Model 3
Covariates Est. SE p [95% CI] Est. SE p [95% CI]
Within-cluster
Age – – – – – − 1.316 0.044 < 0.0001 [− 1.401 − 1.230]
Age2 – – – – – − 0.291 0.026 < 0.0001 [−0.342 − 0.239]
Male – – – – – 0.192 0.046 < 0.0001 [0.102 0.283]
Female – – – – – 0.0 – – – –
Smoker – – – – – − 0.324 0.071 < 0.0001 [− 0.462 −0.185]
Ex-smoker – – – – – −0.175 0.065 0.007 [−0.302 −0.049]
Never smoked – – – – – 0.0 – – – –
Indigenous Australian – – – – – 0.201 0.209 0.336 [−0.209 0.612]
Non- Indigenous Australian – – – – – 0.0 – – – –
Unmarried – – – – – 0.063 0.080 0.426 [−0.093 0.220]
Married – – – – – 0.0 – – – –
N-Comorbidities – – – – – 1.741 0.035 < 0.0001 [1.672 1.811]
Between-cluster
IRSD (Q4) −0.091 0.077 0.241 [−0.242 0.061] 0.361 0.093 < 0.0001 [0.179 0.544]
IRSD (Q3) −0.215 0.056 < 0.0001 [−0.324 −0.107] 0.055 0.071 0.443 [−0.085 0.194]
IRSD (Q2) −0.135 0.047 0.004 [−0.228 −0.042] − 0.020 0.064 0.759 [−0.145 0.105]
IRSD (Q1) 0.0 – – – – 0.0 – – – –
Notes – Age: age in years, standardised; Age2: Age*Age. Smoker: daily, weekly or irregular smoker; Ex-smoker: does not smoke now, but has smoked ≥ 100
cigarettes (or equivalent) in life time; Never smoked: does not smoke now, and has smoked < 100 cigarettes (or equivalent) in life time; Unmarried: never married,
divorced, separated or widowed; Married: registered or de facto; N-Comorbidities: Number of comorbid conditions; IRSD: Index of Relative Social Disadvantage
(ABS 2011); Q1-Q4: National quartile of IRSD (determined using cut-points for quartiles within the Australia-wide distribution of scores at SA1 level) where Q1:
most disadvantaged, Q4: least disadvantaged
Fig. 3 Estimated prevalence of COPD and asthma by SA1
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Fig. 4 Clustering of COPD and Asthma cases (Hot and cold spots)
Fig. 5 Choropleth maps overlaying COPD and asthma prevalence rates with relative socio-economic disadvantage
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(Fig. 5) confirmed the presence of relatively high prevalence
rates of COPD and asthma in low SES areas, but did not
show any specific trend as expected, on the basis of the in-
verse linear relationship previously described.
Discussion
This analysis of GP-based data examined patients’ re-
spiratory conditions and showcased the practical util-
ity of these data for research to improve practitioners’
understandings of chronic disease, and the individual
and geographic factors related to chronic disease and
the potential application for improving health care
practice and patient outcomes [26, 39]. Benchmarked
with age-specific 2014–15 NHS estimates, GP-data re-
vealed lower estimates for COPD up to 64 years, then
higher estimates for age 65 and over. These high-risk
age groups are more likely to be captured by GP
practices than NHS data, as GPs will consider a diag-
nosis of COPD for those patients with a history of
exposure risk factors and comorbid conditions as rec-
ommended by the guidelines [40, 41]. For other pa-
tients, symptoms may appear non-specific and may be
missed, resulting in under-diagnosis of COPD [42,
43]. In relation to asthma, the GP data revealed
higher prevalence values in the 15–25 and 75+ age
groups compared with the NHS-based estimates. In-
deed, patients with childhood asthma may become
asymptomatic, no longer require treatment, or be
missed at diagnosis. However, those that might out-
grow asthma could still develop asthma later on in
their lives, being vulnerable.
These discrepancies may indicate a better under-
standing of the real-world health status and outcomes
that routine GP-practice based data offer as opposed
to self-reported survey-based data. Knowledge of
practice-based versus population discrepancies may
also serve to raise GP awareness and vigilance when
assessing respiratory symptoms, relevant not only to
early detection, but to avoiding delayed detection and
missed opportunities to prevent worsening disease
outcomes [43, 44]. This may be especially important
in age groups for whom the lower prevalence esti-
mates of GP-based data compared with the NHS
could indicate possible under-diagnosis. Finally, these
research findings stand to assist GPs in continuing
education for better management of patients’ multiple
diseases and conditions, and in developing account-
ability benchmarks that could improve patient care –
provided these benchmarks focus on getting the best
outcome for the patient, not simply meeting certain
imposed targets for service delivery [23, 28, 45]. Al-
though this is an idealistic expression of the concept
of putting data back into GP-practices to improve pa-
tients’ outcomes, given substantial differences between
guideline-based and GP-recorded management of
asthma and COPD, this feedback of practice-relevant
information could be a critical component of uptake
of guidelines into daily practice and enhancement of
support strategies available at multiple levels [22].
Other lessons derived from this GP-based data analysis
pertain to the co-occurrence of COPD and asthma with
other chronic conditions, especially COPD-osteoarthritis/
osteoporosis and COPD-mental health (similarly,
asthma-osteoarthritis/osteoporosis and asthma-mental
health) pairs. High rates of co-occurrence were ob-
served among patients aged 55 and over, highlighting
the extent of age-related burden managed by GPs in
routine practice [46, 47]. High rates of co-occurrence
were reported by Britt and Miller in 2013 with COPD
being associated with two or more other chronic dis-
eases in about 87.4% of patients aged 65 years and
over [27]. Other studies have documented the sys-
temic effects of COPD on mental health and the
management of depressive symptoms or severe osteo-
arthritis in patients with COPD [48, 49].
The geographic patterning of COPD and asthma preva-
lence estimates with area-level SES has previously been re-
ported [50]. SES (at both individual and area levels) has
been linked to various health outcomes including asthma
and COPD, with lower SES being associated with higher
rates of morbidity and mortality [14, 50–55]. In this study,
there was a clear negative trend along the areal SES con-
tinuum for COPD with clustering most likely being driven
by the presence of health care services (hospitals and GP
centres) [12, 56]. This may be due to the population in the
study area being mostly multicultural and within the lower
range of SES, except the west coastal region. Moreover,
moderate to severe COPD patients may choose to live closer
to GP centres and local hospitals to improve access time.
The most obvious limitation of this study is the lack of
GP data from other sub-regions in Western Adelaide
plus the wider Adelaide metropolitan area, especially
from areas with higher SES and including Adelaide
CBD. This would have allowed for comparisons of areas
with greater variability in SES and a greater extent of
geographic distributions in prevalence estimates, given
that allied health and other health services tend to be
concentrated in inner urban areas and the CBD. A fur-
ther limitation is a lack of data on clinical variables (e.g.
spirometry) related to COPD and asthma severity and
management, as well as the extent of referrals to special-
ized services including community respiratory services
and rehabilitation centres.
Finally, the samples of practices and patients may not be
representative of Australia, therefore limiting the
generalizability of findings and restricting inferences to the
Adelaide metropolitan region. However, lessons learnt
might more likely have relevance to other metropolitan
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regions in other states or territories in Australia [57]. To
some extent these lessons could be generalised, as most
GP practices use computers and majority code diagnoses
using a range of coding systems. All across Australia, via
primary health networks, efforts have been applied at local
level to improve the quality of GP recorded health data, as
exemplified by the BEACH program data [27] and Magnet
research platform data [28].
Further research is indicated to: clarify reasons for
under-diagnosis and/or over-diagnosis of chronic re-
spiratory conditions in primary care settings [25]; target
disparities in chronic respiratory diseases and potential
correlates, such as psychosocial stressors and built envir-
onment factors [58–60]; and most importantly, highlight
the net benefits of early detection on other patients’ out-
comes such as quality of life, and other comorbid condi-
tions [41, 57, 59].
Conclusion
GP-based research databases are vital to achieving im-
proved understandings of factors that shape patient
outcomes including COPD and asthma, the burden of
disease and comorbid conditions, and levels of disease
management and quality of health care achieved. Al-
though based on a limited number of GP practices in a
geographically specific area, our results highlight the
practical utility of routine GP-based data for quality re-
search that can guide GPs with regard to interventions
including targeted screening and management to im-
prove patient outcomes. Observed spatial patterns sug-
gest that efforts to address inequalities in COPD and
asthma, and their comorbid conditions, should account
for the context of both practices and patient local con-
texts as well as social and environmental barriers to
change. This may require investment in continuing
medical education for professionals, not only to in-
crease their awareness and skills in COPD and asthma
management and control including early diagnosis, but
also to improve clinical coding for these conditions in
GP practices.
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